Markets:

Overview

News

Currencies

International

Treasuries

Amgen (NQ:AMGN)

407.83 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

69 70 Next >

10 Health Care Stocks With Whale Alerts In Today's Session ↗

August 15, 2024

Via Benzinga

Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations ↗

August 15, 2024

The unveiled prices follow months of back-and-forth negotiation between the government and the companies.

Via Investor's Business Daily

Smart Money Is Betting Big In AMGN Options ↗

August 12, 2024

Via Benzinga

MarketBeat Week in Review – 8/5 - 8/9

August 10, 2024

Stocks were looking for direction to end the week, but next week may bring more volatility with the latest reading on inflation and the start of retail earnings

Via MarketBeat

Topics Economy

Amgen Options Trading: A Deep Dive into Market Sentiment ↗

August 08, 2024

Via Benzinga

Amgen's Options: A Look at What the Big Money is Thinking ↗

August 02, 2024

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth $600 Today ↗

July 30, 2024

Via Benzinga

Unpacking the Latest Options Trading Trends in Amgen ↗

July 26, 2024

Via Benzinga

Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review ↗

August 09, 2024

After Monday's panicked global sell-off, markets have calmed down.

Via Investor's Business Daily

The Defensive Sectors And VIX Have NOT Given The All-Clear Signal ↗

August 08, 2024

The market has been a rollercoaster lately, with the resilience of defensive sectors and the modest bounce in the technology sector painting an intriguing picture.

Via Talk Markets

Topics Stocks

Here's Why Eli Lilly Stock Dropped 12% Last Month ↗

August 08, 2024

News from a competitor gave investors an unwelcome dose of reality.

Via The Motley Fool

Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts ↗

August 07, 2024

Amgen posted mixed Q2 results. Analysts highlight upcoming clinical readouts in obesity and inflammatory disease as crucial. Despite some underperformance, growth prospects remain strong, with...

Via Benzinga

Why Amgen Stock Is Down Today Despite Solid Q2 Results ↗

August 07, 2024

Shares may have been likely to fall no matter what the company reported.

Via The Motley Fool

Wall Street Poised For Second Day Of Gains While Bank Of Japan Makes Reassurances; Dollar Strengthens Against Yen, Crude Prices Surge: What's Driving Markets Wednesday? ↗

August 07, 2024

The U.S.

Via Benzinga

Amgen Faces Near-Term Challenges But Long-Term Growth Prospects Remain Strong: Analyst ↗

August 07, 2024

Amgen reported a 20% year-over-year increase in second-quarter sales, reaching $8.39 billion, surpassing the $8.33 billion consensus. Guidance for 2024 includes adjusted EPS of $19.10-$20.10 and...

Via Benzinga

Amgen's MariTide Weight Loss Potential: Stock Outlook

August 07, 2024

Amgen's shares fell 2.4% after-hours trading due to a mixed earnings release. MariTide, the company's weight loss drug, is in Phase II FDA trials.

Via MarketBeat

Topics Intellectual Property

US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity' ↗

August 07, 2024

Wall Street could go from strength to strength as the index futures point to another session in the green as investors seek to put the worst behind. Volatility continued to drop, as evidenced by...

Via Benzinga

Topics Stocks

AMGN Stock Earnings: Amgen Misses EPS, Beats Revenue for Q2 2024 ↗

August 06, 2024

AMGN stock results show that Amgen missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

Amgen Undercuts Its Buy Point On Mixed Second-Quarter Report ↗

August 06, 2024

Amgen stock fell late Tuesday after the biotech reported lighter-than-expected second-quarter profits, though sales beat.

Via Investor's Business Daily

Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday? ↗

August 06, 2024

U.S. stock markets saw a strong recovery on Tuesday, with both the S&P 500 and the Nasdaq 100 climbing over 2%, nearly offsetting Monday’s losses. Investors took advantage of recent volatility to buy...

Via Benzinga

Topics Economy Stocks

Amgen Gears Up For Q2 Print; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

August 06, 2024

Via Benzinga

US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction ↗

August 06, 2024

Strong sell-off may be viewed as an opportunity to load up beaten-down stocks but traders may seek evidence regarding sustainability of uptrend.

Via Benzinga

Topics Stocks

Good Stocks, Strategic Options, and a 4.5% Yield: There's a Lot to Like About This Unique ETF ↗

August 05, 2024

Covered calls can generate income from an investment portfolio but can be complex. This Amplify ETF is a simple solution.

Via The Motley Fool

Topics ETFs

So Much For Expecting The Fed To Stick The Landing ↗

August 04, 2024

Now is not the time to be fully invested.

Via Talk Markets

Topics Economy

3 Biotech Stocks That Could Have Investors Grinning Soon ↗

August 02, 2024

Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential.

Via InvestorPlace

Prediction: This Could Be Amgen's Next Massive Growth Opportunity ↗

August 02, 2024

The innovative biotech is looking for its next blockbuster.

Via The Motley Fool

The Top 3 Biotech Stocks to Buy Now Summer 2024 ↗

July 31, 2024

These biotech stocks are well-positioned to generate high returns for investors due to their significant growth prospects.

Via InvestorPlace

Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations ↗

July 30, 2024

Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 30, 2024

Via Benzinga

3 Dividend-Paying ETFs to Secure Your Passive Income Stream ↗

July 29, 2024

Passive income and ETFs represent two compelling market concepts. Why not bring the two together with dividend-paying ETFs?

Via InvestorPlace

Topics ETFs

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

69 70 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.